Abstract 4358985: Right Ventricular Dysfunction Strongly Predicts Thromboembolism and Major Bleeding in Tetralogy of Fallot and Pulmonary Atresia with Intact Ventricular Septum

M Michael O'Shea (Mayo Clinic, Phoenix, Arizona, United States) S Suganya Arunachalam Karikalan (Mayo Clinic, Phoenix, Arizona, United States) S Srekar Ravi (Mayo Clinic, Phoenix, Arizona, United States) M Matthew van Ligten (Mayo Clinic, Phoenix, Arizona, United States) A Adam Bacon (Mayo Clinic, Phoenix, Arizona, United States) E Eiad Habib (Mayo Clinic Arizona, Scottsdale, Arizona, United States) O Omar Baqal (Mayo Clinic, Phoenix, Arizona, United States) P Philip Smyth (Mayo Clinic, Phoenix, Arizona, United States) W Winston Wang (Mayo Clinic, Phoenix, Arizona, United States) D Dani Green (Mayo Clinic, Phoenix, Arizona, United States) N Nneoma Alozie (Mayo Clinic, Phoenix, Arizona, United States) C Chelsea Marshall (Mayo Clinic, Phoenix, Arizona, United States) A Alexander Egbe H Heidi Connolly (Mayo Clinic, Rochester, Minnesota, United States) M Marlene Girardo (Mayo Clinic, Phoenix, Arizona, United States) H Hicham El Masry (Mayo CLinic AZ, Phoenix, Arizona, United States) D David Majdalany (Mayo Clinic, Phoenix, Arizona, United States)

Abstract

Introduction: Complex congenital heart disease (CHD) patients with atrial arrhythmias have higher rates of morbidity and mortality compared to less complex CHD patients. This study aims to identify echocardiographic predictors of thromboembolism (TE) and major bleeding in patients with Tetralogy of Fallot (ToF) or Pulmonary Atresia with Intact Ventricular Septum (PA-IVS) and atrial fibrillation or flutter (AF). Methods: This cohort study included patients with ToF or PA-IVS who had a diagnosis of AF who underwent a TTE across three sites. Outcomes were incidence rate of major bleeding or TE, calculated using univariable and multivariable cox regression with interaction for anticoagulant choice and fractional area change (FAC). The HAS-BLED score was augmented with major predictors of bleeding, and receiver operator curves compared. Results: We included 300 patients (287 ToF [95.7%], 13 PA-IVS [4.3%]), mean age 45.6 years. Most received warfarin (227 [79.4%]), 40 (13%) used DOACs, and 5 (1.6%) used enoxaparin. TTE predictors of TE included large LVOT diameter ≥3cm (HR 8.92, p=0.002), small LVOT VTI (p=0.014), FAC <30% (HR 7.08, p=0.026) and moderate RV dysfunction (HR 10.75, p=0.026). Predictors of major bleeding included moderate tricuspid regurgitation (HR 2.40, p=0.022), right atrial pressure (1.12, p<0.001), severe RA enlargement (HR 2.30, p=0.048), RV mid diameter (HR 1.06, p=0.005), RV end diastolic area (HR 1.04, p=0.021), RV end systolic area (HR 1.05, p=0.016) elevated RVSP and FAC ≤45% (HR 0.37, p=0.016). Among warfarin users, impaired RV function (FAC ≤45%) was linked to reduced major bleeding events (HR 0.27, p=0.025). There was a nonsignificant trend towards higher bleeding in DOAC users with FAC >45% (HR 3.87, p=0.284), but significantly higher bleeding in DOAC users with FAC ≤45% (HR 12.41, p=0.008) vs. warfarin users with normal RV function (table 1). We developed an augmented HAS-BLED score: the standard score plus one point for moderate-to-severe pulmonic or tricuspid regurgitation and one for FAC ≤45%. This outperformed the standard HAS-BLED in predicting major bleeding (AUC 0.67 augmented vs. 0.57 un-augmented, p=0.008) (figure 1). Conclusion: Echocardiographic evidence of right heart disease is a strong predictor of major bleeding in patients with ToF or PA-IVS. FAC is a useful tool to determine excess major bleeding risk, particularly in DOAC users. Augmenting HAS-BLED with right heart parameters improves diagnostic accuracy.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (17)

M

Michael O'Shea

Mayo Clinic, Phoenix, Arizona, United States

S

Suganya Arunachalam Karikalan

Mayo Clinic, Phoenix, Arizona, United States

S

Srekar Ravi

Mayo Clinic, Phoenix, Arizona, United States

M

Matthew van Ligten

Mayo Clinic, Phoenix, Arizona, United States

A

Adam Bacon

Mayo Clinic, Phoenix, Arizona, United States

E

Eiad Habib

Mayo Clinic Arizona, Scottsdale, Arizona, United States

O

Omar Baqal

Mayo Clinic, Phoenix, Arizona, United States

P

Philip Smyth

Mayo Clinic, Phoenix, Arizona, United States

W

Winston Wang

Mayo Clinic, Phoenix, Arizona, United States

D

Dani Green

Mayo Clinic, Phoenix, Arizona, United States

N

Nneoma Alozie

Mayo Clinic, Phoenix, Arizona, United States

C

Chelsea Marshall

Mayo Clinic, Phoenix, Arizona, United States

A

Alexander Egbe

H

Heidi Connolly

Mayo Clinic, Rochester, Minnesota, United States

M

Marlene Girardo

Mayo Clinic, Phoenix, Arizona, United States

H

Hicham El Masry

Mayo CLinic AZ, Phoenix, Arizona, United States

D

David Majdalany

Mayo Clinic, Phoenix, Arizona, United States